Handelsbanken Fonder AB Decreases Stake in AbbVie Inc. $ABBV

Handelsbanken Fonder AB reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,266,363 shares of the company’s stock after selling 23,442 shares during the quarter. AbbVie accounts for 0.9% of Handelsbanken Fonder AB’s portfolio, making the stock its 15th biggest holding. Handelsbanken Fonder AB owned about 0.07% of AbbVie worth $293,214,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Redmont Wealth Advisors LLC purchased a new position in shares of AbbVie during the third quarter valued at approximately $41,000. Financial Gravity Companies Inc. bought a new position in AbbVie during the second quarter valued at approximately $36,000. Finally, Delos Wealth Advisors LLC purchased a new stake in AbbVie in the second quarter worth approximately $39,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Down 1.0%

Shares of ABBV opened at $224.66 on Friday. The business has a 50-day simple moving average of $224.26 and a two-hundred day simple moving average of $222.71. The stock has a market cap of $397.24 billion, a price-to-earnings ratio of 95.19, a PEG ratio of 0.79 and a beta of 0.35. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Finally, Evercore cut their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.